Sickle Cell Disease - Pipeline Review, H1 2020

April 2020 | 271 pages | ID: S94DCA14DC1EN
Global Markets Direct

Abstracts

Sickle Cell Disease - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sickle Cell Disease - Pipeline Review, H1 2020, provides an overview of the Sickle Cell Disease (Hematological Disorders) pipeline landscape.

Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sickle Cell Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Sickle Cell Disease (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sickle Cell Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 9, 11, 4, 26 and 8 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 1 molecules, respectively.

Sickle Cell Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Sickle Cell Disease (Hematological Disorders).
• The pipeline guide reviews pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Sickle Cell Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Sickle Cell Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Sickle Cell Disease (Hematological Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Sickle Cell Disease (Hematological Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Sickle Cell Disease (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Sickle Cell Disease - Overview
Sickle Cell Disease - Therapeutics Development
Sickle Cell Disease - Therapeutics Assessment
Sickle Cell Disease - Companies Involved in Therapeutics Development
Sickle Cell Disease - Drug Profiles
Sickle Cell Disease - Dormant Projects
Sickle Cell Disease - Discontinued Products
Sickle Cell Disease - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Sickle Cell Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Sickle Cell Disease - Pipeline by Agios Pharmaceuticals Inc, H1 2020
Sickle Cell Disease - Pipeline by Alkermes Plc, H1 2020
Sickle Cell Disease - Pipeline by Angiocrine Bioscience Inc, H1 2020
Sickle Cell Disease - Pipeline by Annexin Pharmaceuticals AB, H1 2020
Sickle Cell Disease - Pipeline by Aruvant Sciences Inc, H1 2020
Sickle Cell Disease - Pipeline by Axcella Health Inc, H1 2020
Sickle Cell Disease - Pipeline by Beam Therapeutics Inc, H1 2020
Sickle Cell Disease - Pipeline by bluebird bio Inc, H1 2020
Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Co, H1 2020
Sickle Cell Disease - Pipeline by C4X Discovery Holdings Plc, H1 2020
Sickle Cell Disease - Pipeline by Cannabis Science Inc, H1 2020
Sickle Cell Disease - Pipeline by Cell Source Inc, H1 2020
Sickle Cell Disease - Pipeline by Cetya Therapeutics Inc, H1 2020
Sickle Cell Disease - Pipeline by CRISPR Therapeutics AG, H1 2020
Sickle Cell Disease - Pipeline by CSL Ltd, H1 2020
Sickle Cell Disease - Pipeline by Cyclerion Therapeutics Inc, H1 2020
Sickle Cell Disease - Pipeline by Dystrogen Therapeutics SA, H1 2020
Sickle Cell Disease - Pipeline by Editas Medicine Inc, H1 2020
Sickle Cell Disease - Pipeline by Emmaus Life Sciences Inc, H1 2020
Sickle Cell Disease - Pipeline by Epidestiny Inc, H1 2020
Sickle Cell Disease - Pipeline by Epizyme Inc, H1 2020
Sickle Cell Disease - Pipeline by Errant Gene Therapeutics LLC, H1 2020
Sickle Cell Disease - Pipeline by ExCellThera Inc, H1 2020
Sickle Cell Disease - Pipeline by Forma Therapeutics Inc, H1 2020
Sickle Cell Disease - Pipeline by Fulcrum Therapeutics Inc, H1 2020
Sickle Cell Disease - Pipeline by Functional Fluidics LLC, H1 2020
Sickle Cell Disease - Pipeline by Gamida Cell Ltd, H1 2020
Sickle Cell Disease - Pipeline by Gilead Sciences Inc, H1 2020
Sickle Cell Disease - Pipeline by Global Blood Therapeutics Inc, H1 2020
Sickle Cell Disease - Pipeline by Glycan Therapeutics Inc, H1 2020
Sickle Cell Disease - Pipeline by Hillhurst Biopharmaceuticals Inc, H1 2020
Sickle Cell Disease - Pipeline by Homology Medicines Inc, H1 2020
Sickle Cell Disease - Pipeline by Imara Inc, H1 2020
Sickle Cell Disease - Pipeline by Intellia Therapeutics Inc, H1 2020
Sickle Cell Disease - Pipeline by Invenux LLC, H1 2020
Sickle Cell Disease - Pipeline by Medeor Therapeutics Inc, H1 2020
Sickle Cell Disease - Pipeline by Merck & Co Inc, H1 2020
Sickle Cell Disease - Pipeline by Micelle BioPharma Inc, H1 2020
Sickle Cell Disease - Pipeline by MimeTech Srl, H1 2020
Sickle Cell Disease - Pipeline by Modus Therapeutics AB, H1 2020
Sickle Cell Disease - Pipeline by Molecules For Health Inc, H1 2020
Sickle Cell Disease - Pipeline by Novartis AG, H1 2020
Sickle Cell Disease - Pipeline by Oryzon Genomics SA, H1 2020
Sickle Cell Disease - Pipeline by PHD Biosciences, H1 2020
Sickle Cell Disease - Pipeline by Phoenicia Biosciences Inc, H1 2020
Sickle Cell Disease - Pipeline by Rare Partners Srl, H1 2020
Sickle Cell Disease - Pipeline by Regenacy Pharmaceuticals LLC, H1 2020
Sickle Cell Disease - Pipeline by ReNeuroGen LLC, H1 2020
Sickle Cell Disease - Pipeline by Sangamo Therapeutics Inc, H1 2020
Sickle Cell Disease - Pipeline by Secura Bio Inc, H1 2020
Sickle Cell Disease - Pipeline by Syros Pharmaceuticals Inc, H1 2020
Sickle Cell Disease - Pipeline by Tarus Therapeutics Inc, H1 2020
Sickle Cell Disease - Pipeline by Trucode Gene Repair Inc, H1 2020
Sickle Cell Disease - Pipeline by Vanguard Therapeutics Inc, H1 2020
Sickle Cell Disease - Dormant Projects, H1 2020
Sickle Cell Disease - Dormant Projects, H1 2020 (Contd..1), H1 2020
Sickle Cell Disease - Dormant Projects, H1 2020 (Contd..2), H1 2020
Sickle Cell Disease - Dormant Projects, H1 2020 (Contd..3), H1 2020
Sickle Cell Disease - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Sickle Cell Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Agios Pharmaceuticals Inc
Alkermes Plc
Angiocrine Bioscience Inc
Annexin Pharmaceuticals AB
Aruvant Sciences Inc
Axcella Health Inc
Beam Therapeutics Inc
bluebird bio Inc
Bristol-Myers Squibb Co
C4X Discovery Holdings Plc
Cannabis Science Inc
Cell Source Inc
Cetya Therapeutics Inc
CRISPR Therapeutics AG
CSL Ltd
Cyclerion Therapeutics Inc
Dystrogen Therapeutics SA
Editas Medicine Inc
Emmaus Life Sciences Inc
Epidestiny Inc
Epizyme Inc
Errant Gene Therapeutics LLC
ExCellThera Inc
Forma Therapeutics Inc
Fulcrum Therapeutics Inc
Functional Fluidics LLC
Gamida Cell Ltd
Gilead Sciences Inc
Global Blood Therapeutics Inc
Glycan Therapeutics Inc
Hillhurst Biopharmaceuticals Inc
Homology Medicines Inc
Imara Inc
Intellia Therapeutics Inc
Invenux LLC
Medeor Therapeutics Inc
Merck & Co Inc
Micelle BioPharma Inc
MimeTech Srl
Modus Therapeutics AB
Molecules For Health Inc
Novartis AG
Oryzon Genomics SA
PHD Biosciences
Phoenicia Biosciences Inc
Rare Partners Srl
Regenacy Pharmaceuticals LLC
ReNeuroGen LLC
Sangamo Therapeutics Inc
Secura Bio Inc
Syros Pharmaceuticals Inc
Tarus Therapeutics Inc
Trucode Gene Repair Inc
Vanguard Therapeutics Inc